LUMIBIRD: REVENUE GROWTH OF+ 12.4% IN THE 1st QUARTER

Core Viewpoint - Lumibird Group reported a consolidated revenue growth of 12.4% in Q1 2025, reaching €49.4 million, driven by strong performance in both the Photonics and Medical divisions [1][3]. Revenue Summary - Consolidated revenues for Q1 2025 were €49.4 million, an increase of 12.4% compared to €43.9 million in Q1 2024, with a constant exchange rate growth of 11.7% [3]. - The Photonics division generated €23.9 million, up 15.8% from €20.6 million in Q1 2024, with a constant exchange rate growth of 15.1% [3][4]. - The Medical division achieved revenues of €25.5 million, reflecting a growth of 9.4% from €23.3 million in Q1 2024, with a constant exchange rate growth of 8.6% [3][6]. Division Performance - The Defence/Space business within the Photonics division saw sales rise by 37.8% to €10.5 million, attributed to multi-year contracts and order book deliveries [4]. - Industrial and Scientific sales increased by 7.0% to €5.9 million, including €0.5 million from the Continuum range acquired in October 2024 [5]. - Medtech sales slightly declined by 2.3% to €3.9 million, impacted by the timing of deliveries throughout 2025 [5]. Geographical Breakdown - EMEA revenues for Photonics were €13.8 million, up 16.2%, while Medical revenues were €7.6 million, down 6.0% [7]. - In the Americas, Photonics revenues increased by 54.1% to €4.5 million, and Medical revenues rose by 2.1% to €6.6 million [7]. - Asia-Pacific Photonics revenues decreased by 17.5% to €2.9 million, while Medical revenues increased by 29.1% to €8.1 million [7]. Future Outlook - Lumibird anticipates continued business expansion driven by growth in Defence/Space and Medical markets, with no significant impact expected from increased customs barriers [10][11].